A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Results of surgically treated BPH patients 6 mo. after surgery (Group I) were compared with those obtained in patients treated with Doxazosin for 3 yrs. (Group II). Surgery provided better improvement in uroflowmetry parameters, residual volume values and obstructive symptom scores (complete relief). Nevertheless, urinary flow rates normalized upon Doxazosin therapy. Higher prostate specific antigen (PSA) levels in Group II may be explained by the greater size of the adenoma. Postoperative adverse events were reported by some patients in contrast with those treated with Doxazosin. Doxazosin, due to its symptomatic and uroflowmetric efficacy, favourable safety profile and simple dosing schedule has a place in the management of symptomatic BPH patients.
Dutkiewicz
S
S
Department of Urology, Central Clinical Hospital, Health Administration of the Capital, Ministry of Internal Affairs, Warsaw, Poland.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery*
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin